Issue 7, 2025

Cu-MOF-based targeted nanomedicine utilizing biorthogonally catalyzed chemotherapy and chemodynamic therapy with spatiotemporal orchestration to treat hepatocellular carcinoma

Abstract

A nanomedicine was developed using a Cu-based metal–organic framework (MOF) to co-deliver Cu(I) and prodrugs for targeted biorthogonally catalyzed chemotherapy and chemodynamic therapy of hepatocellular carcinoma.

Graphical abstract: Cu-MOF-based targeted nanomedicine utilizing biorthogonally catalyzed chemotherapy and chemodynamic therapy with spatiotemporal orchestration to treat hepatocellular carcinoma

Supplementary files

Article information

Article type
Communication
Submitted
04 Nov 2024
Accepted
13 Dec 2024
First published
19 Dec 2024

Chem. Commun., 2025,61, 1415-1418

Cu-MOF-based targeted nanomedicine utilizing biorthogonally catalyzed chemotherapy and chemodynamic therapy with spatiotemporal orchestration to treat hepatocellular carcinoma

X. Wan, Y. Zhang, H. Zhang, W. Pan, X. Qiao, N. Li and B. Tang, Chem. Commun., 2025, 61, 1415 DOI: 10.1039/D4CC05890A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements